Investing in Innovation.Building the Next Generation of Therapeutics.
ACS Biomed develops proprietary pharmaceutical and medical technologies focused on dermatology, ophthalmology and advanced medical devices. Our mission is to transform innovative research into globally commercialized healthcare solutions through scientific excellence, strategic partnerships and international development.
Company at a Glance
The pillars that define ACS Biomed — from intellectual property and commercial validation to clinical development and manufacturing strategy.
The LATAM figure represents contracted minimum purchase obligations to be fulfilled over a five-year term, not revenue already collected or recognized.
Proprietary Technologies
Innovative therapeutic platforms protected by proprietary know-how and intellectual property.
Commercial Validation
International commercialization strategy supported by executed distribution agreements and ongoing global expansion.
Clinical Development
Multiple development programs advancing through regulatory and clinical pathways.
Manufacturing Strategy
Industrial manufacturing scale-up supported by GMP production partners.
The Portfolio: 4 Assets
ACS Biomed holds 4 proprietary assets: 2 already-commercialized products and 3 active development programs. ErpeCream counts toward both — it is already commercialized as a dermocosmetic gel while separately advancing through clinical development as a pharmaceutical program for recurrent genital HSV.
ErpeCream®
Dermocosmetic gel already commercialized, paired with a clinical-stage pharmaceutical program (Phase IIb ongoing, Phase III planned) toward registration as a prescription treatment for recurrent genital HSV.
ErpeLips™
Commercialized topical cream for cold sore (herpes labialis) lesions, distributed across the EU/UK with regional expansion underway.
ACRO-EYE™
Proprietary ophthalmic technology for ocular surface and dry eye disease, advancing through development toward its regulatory pathway.
Easy-Dialysis™
Advanced medical device for dialysis, currently in industrial development toward CE certification.
Our Development Pipeline
Our proprietary technologies advance along a structured pathway, from research to global commercialization. The highlighted stage marks each program's current position.
ErpeCream®
Pharmaceutical Development · Recurrent Genital HSVClinical-stage pharmaceutical program advancing the same nanoemulsion platform already commercialized as the ErpeCream dermocosmetic gel, now in development toward registration as a prescription treatment for recurrent genital HSV infection.
ACRO-EYE™
Ophthalmology · Ocular surfaceProprietary ophthalmic technology for ocular surface and dry eye disease, advancing through development toward its regulatory pathway.
Easy-Dialysis™
Medical device · NephrologyAdvanced medical device designed to make dialysis simpler and safer, currently in industrial development toward CE certification.
Why ACS Biomed
Scientific Innovation
Development of proprietary therapeutic technologies addressing significant unmet medical needs.
Commercial Strategy
International commercialization through licensing and exclusive distribution partnerships.
Long-Term Vision
Building an integrated pharmaceutical company with a scalable manufacturing network through qualified GMP partners and global commercial reach.
Partnering for Long-Term Value Creation
ACS Biomed collaborates with strategic, institutional and qualified financial partners who share our long-term vision of developing innovative healthcare technologies. Our objective is to create sustainable value through disciplined clinical development, regulatory execution and international commercialization.
Participation Opportunities
Strategic Equity
For investors interested in participating in the long-term growth of ACS Biomed through equity participation.
Institutional & Strategic Partnerships
Designed for pharmaceutical companies, family offices and institutional investors interested in strategic collaborations, licensing opportunities or co-development initiatives.
Clinical Program Financing
Selected clinical development programs may be financed through individually negotiated financing agreements with qualified counterparties.
These arrangements are evaluated exclusively on a case-by-case basis following direct engagement and are not publicly offered.
Value Creation Strategy
Why Investors Engage With ACS Biomed
Governance & Team
ACS Biomed is led by an experienced team and supported by a network of scientific advisors and high-level clinical and manufacturing partners.
Management Team
Led by experienced pharmaceutical and life-sciences executives overseeing corporate strategy, clinical development and commercialization.
Scientific & Advisory Board
Dermatology, virology and ophthalmology experts guiding research direction and clinical study design.
Clinical Partners
International CROs and qualified clinical sites executing our regulated studies.
Manufacturing Partners
GMP / ISO-certified production partners ensuring pharmaceutical-grade quality and industrial scalability.
Speak with Our Investment Team
Qualified investors interested in learning more about ACS Biomed, our clinical development programs or potential strategic collaborations are invited to contact our Investor Relations team for confidential discussions.
The information provided on this page is intended solely for general corporate communication purposes and does not constitute a public offer of financial instruments, investment solicitation or investment advice. Any potential financing or investment opportunity is evaluated exclusively through individual discussions and, where applicable, formal contractual documentation in accordance with applicable laws and regulations.